We are analyzing https://link.springer.com/article/10.1007/s00262-016-1897-3.

Title:
Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes | Cancer Immunology, Immunotherapy
Description:
Melanoma is one of the most immunogenic tumors, and extensive lists of potential tumor rejection antigens have been collected during the last decades. By isolating human leukocyte antigen (HLA) class I complexes from five melanoma cell lines (FM-82, FM-93/2, Mel-624, MeWo and SK-Mel-5) and sequencing HLA-eluted peptides by mass spectrometry, we identified over 10,000 unique peptides with high confidence. The majority of the peptides were 8–11 amino acids in length and were predicted to bind to the respective HLA alleles. Over 250 epitopes, corresponding to previously described tumor-associated antigens, were identified, suggesting that HLA peptidome analysis may facilitate the characterization of putative tumor rejection antigens. MeWo and SK-Mel-5 cell lines were further interrogated for neo-epitopes, revealing one peptide from MeWo cells carrying an amino acid mutation. We also observed a remarkable overlap between A*03:01 peptides eluted from Mel-624 cells and A*03:01 peptides recovered from soluble HLA complexes purified from two melanoma patients, shedding light on the similarity of the HLA peptidome in cell lines and in patient-derived material. The reliable characterization of the HLA class I peptidome in melanoma promises to facilitate the identification of tumor rejection antigens and the development of immunotherapeutic strategies.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 8,149,968 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

article, pubmed, google, scholar, cas, cancer, hla, cell, human, melanoma, central, class, lines, antigen, peptide, mass, peptides, cells, science, analysis, peptidome, identification, antigens, schumacher, immunol, fugmann, neri, tumor, leukocyte, access, mhc, therapy, privacy, cookies, content, research, immunotherapy, tumorassociated, epitopes, ritz, spectrometry, nielsen, data, european, publish, search, gloger, tim, dario, high,

Topics {✒️}

month download article/chapter anti-ctla-4 therapy broadens proteome-wide protein quantification adoptively transferred tumor-reactive cells targeting ny-eso-1 high-sensitivity hla class melanoma-specific human cytotoxic t-cell antigen specificity article cancer immunology immunogenic t-cell epitopes full article pdf sequencing hla-eluted peptides european research council peptide mhc class web server issue sk-mel-5 cell lines privacy choices/manage cookies antigen-specific cd8+ peptide-binding specificities mass spectrometric analysis adoptive cellular therapy tumor rejection antigens article gloger borresen-dale al database issue related subjects immune checkpoint therapy peptidome analysis enables european economic area mhc-based detection mhc motif viewer human gastrointestinal cancers tumor antigens recognized melanoma tumor cells range mass accuracies analytics accurately identify melanoma-reactive cd8+ grant agreement nos amino acid mutation amino acid enrichment melanoma cell lines hadrup sr adoptive cell transfer respective hla alleles cancer genome landscapes il-2-based treatment de ru ah del prete gq hiv-infected cells de vries ij

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes
         description:Melanoma is one of the most immunogenic tumors, and extensive lists of potential tumor rejection antigens have been collected during the last decades. By isolating human leukocyte antigen (HLA) class I complexes from five melanoma cell lines (FM-82, FM-93/2, Mel-624, MeWo and SK-Mel-5) and sequencing HLA-eluted peptides by mass spectrometry, we identified over 10,000 unique peptides with high confidence. The majority of the peptides were 8–11 amino acids in length and were predicted to bind to the respective HLA alleles. Over 250 epitopes, corresponding to previously described tumor-associated antigens, were identified, suggesting that HLA peptidome analysis may facilitate the characterization of putative tumor rejection antigens. MeWo and SK-Mel-5 cell lines were further interrogated for neo-epitopes, revealing one peptide from MeWo cells carrying an amino acid mutation. We also observed a remarkable overlap between A*03:01 peptides eluted from Mel-624 cells and A*03:01 peptides recovered from soluble HLA complexes purified from two melanoma patients, shedding light on the similarity of the HLA peptidome in cell lines and in patient-derived material. The reliable characterization of the HLA class I peptidome in melanoma promises to facilitate the identification of tumor rejection antigens and the development of immunotherapeutic strategies.
         datePublished:2016-09-06T00:00:00Z
         dateModified:2016-09-06T00:00:00Z
         pageStart:1377
         pageEnd:1393
         sameAs:https://doi.org/10.1007/s00262-016-1897-3
         keywords:
            HLA
            Melanoma
            Immunopeptidome
            Tumor-associated antigen
            Mass spectrometry
            Immunocapture
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-016-1897-3/MediaObjects/262_2016_1897_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-016-1897-3/MediaObjects/262_2016_1897_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-016-1897-3/MediaObjects/262_2016_1897_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-016-1897-3/MediaObjects/262_2016_1897_Fig4_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:65
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Andreas Gloger
               affiliation:
                     name:ETH Zurich
                     address:
                        name:Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Danilo Ritz
               affiliation:
                     name:Philochem AG
                     address:
                        name:Philochem AG, Otelfingen, Switzerland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Tim Fugmann
               affiliation:
                     name:Philochem AG
                     address:
                        name:Philochem AG, Otelfingen, Switzerland
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Dario Neri
               affiliation:
                     name:ETH Zurich
                     address:
                        name:Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes
      description:Melanoma is one of the most immunogenic tumors, and extensive lists of potential tumor rejection antigens have been collected during the last decades. By isolating human leukocyte antigen (HLA) class I complexes from five melanoma cell lines (FM-82, FM-93/2, Mel-624, MeWo and SK-Mel-5) and sequencing HLA-eluted peptides by mass spectrometry, we identified over 10,000 unique peptides with high confidence. The majority of the peptides were 8–11 amino acids in length and were predicted to bind to the respective HLA alleles. Over 250 epitopes, corresponding to previously described tumor-associated antigens, were identified, suggesting that HLA peptidome analysis may facilitate the characterization of putative tumor rejection antigens. MeWo and SK-Mel-5 cell lines were further interrogated for neo-epitopes, revealing one peptide from MeWo cells carrying an amino acid mutation. We also observed a remarkable overlap between A*03:01 peptides eluted from Mel-624 cells and A*03:01 peptides recovered from soluble HLA complexes purified from two melanoma patients, shedding light on the similarity of the HLA peptidome in cell lines and in patient-derived material. The reliable characterization of the HLA class I peptidome in melanoma promises to facilitate the identification of tumor rejection antigens and the development of immunotherapeutic strategies.
      datePublished:2016-09-06T00:00:00Z
      dateModified:2016-09-06T00:00:00Z
      pageStart:1377
      pageEnd:1393
      sameAs:https://doi.org/10.1007/s00262-016-1897-3
      keywords:
         HLA
         Melanoma
         Immunopeptidome
         Tumor-associated antigen
         Mass spectrometry
         Immunocapture
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-016-1897-3/MediaObjects/262_2016_1897_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-016-1897-3/MediaObjects/262_2016_1897_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-016-1897-3/MediaObjects/262_2016_1897_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-016-1897-3/MediaObjects/262_2016_1897_Fig4_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:65
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Andreas Gloger
            affiliation:
                  name:ETH Zurich
                  address:
                     name:Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Danilo Ritz
            affiliation:
                  name:Philochem AG
                  address:
                     name:Philochem AG, Otelfingen, Switzerland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Tim Fugmann
            affiliation:
                  name:Philochem AG
                  address:
                     name:Philochem AG, Otelfingen, Switzerland
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Dario Neri
            affiliation:
                  name:ETH Zurich
                  address:
                     name:Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:65
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:ETH Zurich
      address:
         name:Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
         type:PostalAddress
      name:Philochem AG
      address:
         name:Philochem AG, Otelfingen, Switzerland
         type:PostalAddress
      name:Philochem AG
      address:
         name:Philochem AG, Otelfingen, Switzerland
         type:PostalAddress
      name:ETH Zurich
      address:
         name:Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Andreas Gloger
      affiliation:
            name:ETH Zurich
            address:
               name:Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
               type:PostalAddress
            type:Organization
      name:Danilo Ritz
      affiliation:
            name:Philochem AG
            address:
               name:Philochem AG, Otelfingen, Switzerland
               type:PostalAddress
            type:Organization
      name:Tim Fugmann
      affiliation:
            name:Philochem AG
            address:
               name:Philochem AG, Otelfingen, Switzerland
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Dario Neri
      affiliation:
            name:ETH Zurich
            address:
               name:Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
      name:Philochem AG, Otelfingen, Switzerland
      name:Philochem AG, Otelfingen, Switzerland
      name:Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(189)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.56s.

LINK . SPRINGER . COM {}